Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study will test the safety, tolerability, and bioeffects (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in hyperlipidemic patients with or without atorvastatin therapy. The study drug and placebo will be administered by subcutaneous injection at the clinic. There will be a total of 2 or 3 study drug injections over 16 clinic visits, which will include 3 overnight stays(study duration 148 days, not including the screening period). Patients on atorvastatin will take their daily dose in the morning for the duration of the study. Patients will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs(blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single to Multi-Dose Study of Safety, Tolerability, and Bioeffect of Subcutaneously Administered REGN727 in Patients With and Without Concomitant Atorvastatin
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in hyperlipidemic patients treated with REGN727 or placebo receiving stable doses of atorvastatin. [ Time Frame: visit 4 (day 1) to visit 16 (day 148) ]
Secondary Outcome Measures
To assess the pharmacodynamic effect of REGN727 added to atorvastatin on lipids [ Time Frame: Visit 4 (Day 1) to Visit 16 (Day 148) ]
To assess the pharmacodynamic effect of monotherapy REGN727 in hyperlipidemic patients [ Time Frame: Visit 4 (Day 1) to Visit 16 (Day 148) ]
To assess the pharmacokinetics of REGN727 in hyperlipidemic patients with or without atorvastatin [ Time Frame: Visit 4 (Day 1) to Visit 16 (Day 148) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Men and women with elevated cholesterol on stable doses of atorvastatin 10-40mg/day regimen
Body mass index between 18.0 and 35.0 kg/m2, inclusive
For women of childbearing potential, a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day -2 or day -1
For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner[s] become pregnant)during the full duration of the study
Willing, committed and able to return for all the clinic visits and complete all study-related procedures
Able to read, and able to sign the informed consent form
History of MI, ACS, Angina, Stroke, peripheral vascular disease, or cardiac revascularization
Pregnant or breast-feeding women
Blood donation of any volume within 1 month prior to administration of study drug
Congestive heart failure
Consumption of greater than 1 quart of grapefruit juice per day
Previous exposure to any therapeutic or investigational biological agent within 30 days of screening
History of alcohol or drug abuse within one year to the screening visit
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.